Research programme: gene-silencing oligonucleotides - GSK/Idera

Drug Profile

Research programme: gene-silencing oligonucleotides - GSK/Idera

Alternative Names: Renal disease therapeutics - Idera/GSK; Third generation antisense-based therapeutics - GSK/Idera

Latest Information Update: 03 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Idera Pharmaceuticals
  • Developer GlaxoSmithKline; Idera Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Renal failure

Most Recent Events

  • 23 Nov 2015 Early research in Renal failure in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top